Palatin Technologies has some changes to make for the upcoming trials of the dry eye disease drug PL9643 after the phase 3 MELODY-1 study failed on the main goal of improving a clinical sign of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results